Safety of infliximab in clinical trials

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 4, 1999, Pages 16-22

  Hanauer, S B ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

AUTOIMMUNE DISEASE; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG SAFETY; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ADULT; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; FEMALE; LYMPHOPROLIFERATIVE DISEASE; MALE; MIDDLE AGED; REVIEW;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED;

EID: 0032848211     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Torgan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
2. Rutgeerts P, D'Haens G, van Deventer SJH, et al. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997; 112 (4 Suppl.): A1078. (Abstract).
3. Present D, Mayer L, van Deventer SJH, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: a multi-center, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1997; 92: 1746. (Abstract).
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
5. ™ (infliximab) Prescribing Information. Centocor, Inc., Malvern, PA, August 1998.
6. Schur PH. Systemic lupus erythematosus. In: Bennet JC, Plum F, eds. Cecil Textbook of Medicine, 30th edn., W.B. Saunders, Co., Philadelphia, 1996: 1475-83.
7. Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69: 1119-23.
8. Myllykangas-Luosujarvi R, Aho K, Isomaki H. Morbidity from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 76-8.
9. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11.
10. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.